AQS fundamentals

Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.